Immune System News and Research

RSS

Novel method could help advance fight against persistent 'HIV latency'

Scientists at the Gladstone Institutes have gotten us one step closer to understanding and overcoming one of the least-understood mechanisms of HIV infection-by devising a method to precisely track the life cycle of individual cells infected with HIV, the virus that causes AIDS.

12 Sep 2012

New model reveals how immune system functions under conditions of neutropenia

Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the number of white blood cells falls below a critical threshold, the risk of infection is thought to be high.

12 Sep 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

Blocking GSK3b enzyme can prevent bacterial-induced periodontal bone loss

A University of Louisville scientist has found a way to prevent inflammation and bone loss surrounding the teeth by blocking a natural signaling pathway of the enzyme GSK3b, which plays an important role in directing the immune response.

12 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

A research study conducted by Dr. Jesus Lovera, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has found that the herbal supplement Ginkgo biloba does not improve cognitive function in patients with Multiple Sclerosis (MS).

12 Sep 2012

BRI scientists receive two major grant awards for research into autoimmunity prevention

Benaroya Research Institute at Virginia Mason (BRI) recently received two major grant awards to explore how to regulate the immune system, as part of a nationwide collaborative program to prevent autoimmune diseases.

11 Sep 2012

First demonstration of newly developed dual humanized FRGTM KO system against malaria

A novel human liver-chimeric mouse model developed at Oregon Health & Science University and Yecuris Corporation has made possible a research breakthrough at Seattle Biomedical Research Institute that will greatly accelerate studies of the most lethal forms of human malaria.

11 Sep 2012

Polysaccharopeptide improves survival in dogs with hemangiosarcoma

Dogs with hemangiosarcoma that were treated with a compound derived from the Coriolus versicolor mushroom had the longest survival times ever reported for dogs with the disease.

11 Sep 2012

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of LL-37 for the treatment of patients with hard-to-heal venous leg ulcers.

11 Sep 2012

Researchers discover small DNA sequence that drives GATA2 protein

The protein GATA2 is known as a "master regulator" of blood cell development. When a mutation occurs in the gene that makes GATA2, serious blood diseases such as acute myeloid leukemia can result.

11 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Scientists used genetic sequencing to discover new evidence that the first vaccine shown to prevent HIV infection in people also affected the viruses in those who did become infected. Viruses with two genetic "footprints" were associated with greater vaccine efficacy. The results were published today in the online edition of the journal Nature.

10 Sep 2012

Automated system for mapping protein-DNA interactions

Since the sequencing of the human genome in 2001, all our genes - around 20,000 in total - have been identified. But much is still unknown - for instance where and when each is active. Next to each gene sits a short DNA segment, and the activity of this regulatory segment determines whether the gene will be turned on, where and how strongly.

10 Sep 2012

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

10 Sep 2012

Immune System News and Research

Novel method could help advance fight against persistent 'HIV latency'

New model reveals how immune system functions under conditions of neutropenia

Scripps scientists discover new antibody-discovery technique

Blocking GSK3b enzyme can prevent bacterial-induced periodontal bone loss

KaloBios commences KB003 Phase 2 trial in severe asthma

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

BRI scientists receive two major grant awards for research into autoimmunity prevention

First demonstration of newly developed dual humanized FRGTM KO system against malaria

Polysaccharopeptide improves survival in dogs with hemangiosarcoma

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Researchers discover small DNA sequence that drives GATA2 protein

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Combining two drugs may offer new and potent punch against cancer and other diseases

Oxyphenbutazone can kill drug resistant TB

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Automated system for mapping protein-DNA interactions

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Surprising new roles for angiotensin converting enzyme

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News